alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 15


Acknowledgement Letter of Independent Certified Public Accountants





The Board of Directors


Catalina Marketing Corporation:





We are aware of the incorporation
by reference in the Registration Statements (Form S-8 No. 33-46793, Form S-8 No. 33-77100, Form S-8 No. 33-82456, Form S-8 No. 333-07525 and Form S-8 No. 333-86905) of Catalina Marketing Corporation of our report relating to the unaudited condensed
consolidated interim financial statements as of June 30, 2002 and for the three-month period then ended of Catalina Marketing Corporation that are included in its Form 10-Q for the quarter ended June 30, 2002.





/s/ Ernst & Young LLP





August 13, 2002


Tampa, Florida
Exhibit








FIRST AMENDMENT TO
EMPLOYMENT AGREEMENT


This First Amendment (the “Amendment”) is dated effective January 1, 2019 and amends the Employment Agreement by and between Umpqua Holdings Corporation (“Umpqua”) and Andrew Ognall (“Officer”) dated as of May 1, 2014 (the “Employment Agreement”).


1.    PURPOSE OF AMENDMENT AND DURATION OF AGREEMENT.  


1.1    The purpose of this Amendment is to extend the term of the Employment Agreement, which is set to expire December 31, 2018, and to amend certain provisions of the Employment Agreement as set forth below.


1.2    The duration of the Employment Agreement is hereby amended and extended to December 31, 2019, unless sooner terminated as set forth in the Employment Agreement.


2.    SEVERANCE. The first sentence of Section 9 of the Employment Agreement is amended to change the Severance Benefit and replaced with the following: “In the event of Termination Without Cause or Termination for Good Reason, in addition to receiving Earned Compensation, Officer will receive a severance benefit equal to twelve months Base Salary (the ‘Severance Benefit’).”


3.    TRADE SECRETS. The following provision is added to Section 17 of the Agreement:


“NOTICE OF IMMUNITY UNDER THE ECONOMIC ESPIONAGE ACT OF 1996, AS AMENDED BY THE DEFEND TRADE SECRETS ACT OF 2016: Notwithstanding any other provision of this Agreement: (A) Officer will not be held criminally or civilly liable under any federal or state trade secret law for any disclosure of a trade secret that is made: (1) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney and solely for the purpose of reporting or investigating a suspected violation of law; or (2) in a complaint or other document that is filed under seal in a lawsuit or other proceeding; and (B) if Officer files a lawsuit for retaliation by Umpqua for reporting a suspected violation of law, Officer may disclose Umpqua’s trade secrets to Officer’s attorney and use the trade secret information in the court proceeding if Officer (1) files any document containing the trade secret under seal; and (2) does not disclose the trade secret, except pursuant to court order.”


4.    EFFECT OF AMENDMENT.  Except as specifically set forth herein, the Employment Agreement shall continue in full force and effect as written.




1









5.    DEFINED TERMS.  Capitalized terms not otherwise defined in this Amendment have the meanings set forth in the Employment Agreement.


UMPQUA HOLDINGS CORPORATION




By:    /s/ Sheri Burns            
Title:    EVP/Chief People Officer    


OFFICER
    
/s/ Andrew Ognall        
Andrew Ognall


2
**Exhibit 32.1**

 

Certification Pursuant to18 U.S.C. Section 1350,as Adopted Pursuant toSection 906 of the Sarbanes-Oxley Act of 2002

 

In connection with the quarterly report of Morton’s Restaurant Group, Inc. (“Morton’s”) on Form 10-Q for the quarter ended April 3, 2005, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Allen J. Bernstein, the Chief Executive Officer of Morton’s, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(i) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

 

(ii) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Morton’s.

 

Date: May 17, 2005

 
|   | /s/ ALLEN J. BERNSTEIN  |   |
|--------|-------------------------|--------|
|   | Allen J. Bernstein      |
|   | Chief Executive Officer |

 

----
Michael Lee SMITH, Appellant, v. STATE of Florida, Appellee.

No. 1D18-0163

District Court of Appeal of Florida, First District.

May 2, 2018

Michael Lee Smith, pro se, Appellant.

Pamela Jo Bondi, Attorney General, Tallahassee, for Appellee.

Per Curiam.

AFFIRMED .

Osterhaus, Winokur, and M.K. Thomas, JJ., concur.
IIB 

118TH CONGRESS 

2D SESSION H. R. 6011 

IN THE SENATE OF THE UNITED STATES 

APRIL 15 (legislative day, APRIL 10), 2024 

Received 

APRIL 15, 2024 

Read twice and referred to the Committee on Energy and Natural Resources 

AN ACT 

To direct the Secretary of the Interior and the Secretary 

of Agriculture to notify applicants of the completion status of right-of-way applications under section 501 of 

the Federal Land Policy and Management Act of 1976 

and section 28 of the Mineral Leasing Act. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

HR 6011 RFS

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘Right-Of-Way Applica3 tion Transparency and Accountability Act’’ or the 

4 ‘‘ROWATA Act’’. 

5 SEC. 2. DETERMINATION REGARDING RIGHTS-OF-WAY. 

6 (a) NOTICE.—Not later than 90 days after the Sec7 retary concerned receives an application to grant a right8 of-way, the Secretary concerned shall— 

9 (1) notify the applicant as to whether the appli10 cation is complete; or 

11 (2) notify the applicant that information is 

12 missing and specify any information that is required 

13 to be submitted for the application to be complete. 

14 (b) DEFINITIONS.—In this Act: 

15 (1) RIGHT-OF-WAY.—The term ‘‘right-of-way’’ 

16 means— 

17 (A) a right-of-way issued, granted, or re18 newed under section 501 of the Federal Land 

19 Policy and Management Act of 1976 (43 U.S.C. 

20 1761); or 

21 (B) a right-of-way granted under section 

22 28 of the Mineral Leasing Act (30 U.S.C. 185). 

23 (2) SECRETARY CONCERNED.—The term ‘‘Sec24 retary concerned’’ means— 

25 (A) with respect to public lands, the Sec26 retary of the Interior; and 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
3 

HR 6011 RFS

1 (B) with respect to National Forest Sys2 tem lands, the Secretary of Agriculture. 

Passed the House of Representatives April 11, 2024. 

Attest: KEVIN F. MCCUMBER, 

Clerk. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
<PAGE>

EXHIBIT 99.20
-------------

Contact:          Jerry B. Hook, Ph.D.
                  President & CEO
                  Sparta Pharmaceuticals, Inc.
                  (215) 442-1700, ext. 205

FOR IMMEDIATE RELEASE

            Sparta Pharmaceuticals, Inc. Announces Award of $750,000
            --------------------------------------------------------

         Horsham, PA, September 22, 1997 -- Sparta Pharmaceuticals, Inc.
(Nasdaq: SPTA, SPTAU, SPTAW, SPTAZ and SPTAL) announced today that the Company
has been awarded a Phase 2 Small Business Innovation Research (SBIR) Grant by
the National Institute of Neurological Disorders and Stroke (NINDS).

This $750,000 grant will be received over two years. The grant entitled "A Novel
Recombinant Serpin for the Treatment of Stroke" will provide funds for the
continued development of the Company's most advanced serine protease inhibitor,
LEX 032, for the treatment of reperfusion injury. LEX 032 has the potential of
benefitting stroke patients after treatment with a thrombolytic agent such as
tPA and other acute life threatening inflammatory conditions such as ARDS and
traumatic injury. The specific goals of the grant are to scale-up manufacturing,
develop additional preclinical efficacy data and complete initial toxicology
studies.

Dr. Jerry B. Hook, Sparta's President and Chief Executive Officer, said
"Receiving this grant is a major event for the Company. The award provides
resources for the development of this promising asset and also provides peer
review validation of the science underpinning this compound."

Sparta is a development stage pharmaceutical company engaged in the business of
acquiring rights to, and developing for commercialization, technologies and
drugs for the treatment of a number of life threatening diseases including
cancer, cardiovascular disorders and inflammation. The Company has focused on
acquiring compounds that have been previously tested in humans and animals and
technologies that may improve the delivery or targeting of previously tested,
and in some cases marketed, anticancer agents. Sparta's foundation in cancer
chemotherapy has been augmented by the addition of new technology in the rapidly
expanding field of serine protease inhibitors. Serine protease inhibitors have
wide applications in diverse fields such as inflammation, reperfusion injury and
stroke.

                                      # # #
Hemant N. SHAH, M.D., Appellant/Petitioner(s), v. REGIONS BANK, et al., Appellee/Respondent(s).

CASE NO.: 2D16-5538

District Court of Appeal of Florida, Second District.

October 31, 2017

BY ORDER OF THE COURT:

Pursuant to the notice of voluntary dismissal filed herein, this appeal is dismissed.
Exhibit 23.1


            CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


We hereby consent to the incorporation by reference in the Registration
Statements of Tasker Capital Corp. on Form S-2 (Registration Nos. 333-115514,
333-119065, 333-121052, 333-122383) and Form S-8 (Registration No. 333-121054)
of our report dated March 31, 2005, relating to the consolidated financial
statements which appears in the Annual Report on Form 10-KSB for the year ended
December 31, 2004.


                                             /s/ Rothstein, Kass & Company, P.C.


Roseland, New Jersey
April 29, 2005
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Environmental Protection Agency

          - [FRL OP-OFA-003]

*Responsible Agency:*                     Office of Federal Activities, General Information 202-564-5632 or                     *https://www.epa.gov/​nepa.*

Weekly Receipt of Environmental Impact Statements (EIS)

Filed January 31, 2022 10 a.m. EST Through February 7, 2022 10 a.m. EST

Pursuant to 40 CFR 1506.9.

## Notice

                    Section 309(a) of the Clean Air Act requires that EPA make public its comments on EISs issued by other Federal agencies. EPA's comment letters on EISs are available at:                     *https://cdxnodengn.epa.gov/​cdx-enepa-public/​action/​eis/​search.*

*EIS No. 20220013, Draft Supplement, USFS, NAT*, Nationwide Aerial Application of Fire Retardant on National Forest System Land,                     *Comment Period Ends:*                     03/29/2022,                     *Contact:*                     Laura Conway 406-802-4317                

## Amended Notice:

*EIS No. 20210187, Draft, USFS, UT,*                     Southern Monroe Mountain Allotments Livestock Grazing Authorization,                     *Comment Period Ends:*                     02/22/2022,                     *Contact:*                     Jason Kling 435-896-1080. Revision to FR Notice Published 12/23/2021; Extending the Comment Period from 02/07/2022 to 02/22/2022.                

*EIS No. 20220003, Draft, BLM, UT,*                     Pine Valley Water Supply Project,                     *Comment Period Ends:*                     03/11/2022,                     *Contact:*                     Brooklynn Cox 435-865-3073. Revision to FR Notice Published 01/07/2022; Extending the Comment Period from 02/22/2022 to 03/11/2022.                

Dated: February 7, 2022.

Cindy S. Barger,

Director, NEPA Compliance Division, Office of Federal Activities.

[FR Doc. 2022-02959 Filed 2-10-22; 8:45 am]

BILLING CODE 6560-50-P
Anthony VARGAS, Appellant, v. STATE of Florida, Appellee.

Case No. 5D17-3073

District Court of Appeal of Florida, Fifth District.

Decision filed March 6, 2018

**DECISION WITHOUT PUBLISHED OPINION**

AFFIRMED.
<PAGE>


                                                                    Exhibit 99.1

                                  CERTIFICATION
                       PURSUANT TO 18 U.S.C. SECTION 1350,
           AS ADOPTED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

          I, Lawrence S. Hershfield, as Chief Executive Officer of The FINOVA
Group Inc. (the "Company") certify, pursuant to 18 U.S.C. (S) 1350, as adopted
by Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

          (1)  the accompanying Form 10-Q report for the period ending June 30,
2002 as filed with the U.S. Securities and Exchange Commission (the "Report")
fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934, as amended; and

          (2)  the information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.

Dated: August 14, 2002
                                      /s/ Lawrence S. Hershfield
                                      -------------------------------
                                      Lawrence S. Hershfield,
                                      Chief Executive Officer
Michael R. PRESLEY, Esq., Appellant/Petitioner(s), v. Roberta Sue CASSELBERRY, Appellee/Respondent(s).

CASE NO.: 2D18-0696

District Court of Appeal of Florida, Second District.

May 18, 2018

BY ORDER OF THE COURT:

Petitioner's petition for writ of prohibition is denied.

KELLY, BLACK, and LUCAS, JJ., Concur.
EX PARTE Robert INGRAM

CR-16-0526

Court of Criminal Appeals of Alabama.

May 15, 2017

**DECISION WITHOUT PUBLISHED OPINION**

Mand. pet. denied.
Exhibit 31.1





CERTIFICATION PURSUANT TO


SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002





I, Stephen C. Taylor, certify that:





1. I have reviewed this Amendment #1 to Annual Report on Form 10-K/A of Natural Gas Services Group, Inc.; and





2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.





Date: April 29, 2022/s/ Stephen C. TaylorStephen C. TaylorPresident and Chief Executive Officer(Principal Executive Officer)
#### VIRNETX INC., Appellant v. APPLE, INC., Appellee

2016-1480

United States Court of Appeals, Federal Circuit.

Decided: December 9, 2016

Igor Victor Timofeyev, Paul Hastings LLP, Washington, DC, argued for appellant. Also represented by Naveen Modi, Joseph Palys, Danielle Ruth Acker Sus-anj, Daniel Zeilberger.

John C. O’quinn, Kirkland & Ellis LLP, Washington, DC, argued for appellee. Also represented by Nathan S. Mammen; Jeffrey Paul Kushan, Sidley Austin LLP, Washington, DC.

Before O’Malley, Mayer, and Wallaeh, Circuit Judges.

O’Malley, Circuit Judge.

This appeal concerns the validity of VirnetX Inc.’s (“VirnetX”) U.S. Patent No. 8,051,181 (“the ’181 patent”), disclosing technology for establishing secure communication over networks. Apple Inc. (“Apple”) challenged all claims of the ’181 patent in a request for *inter partes*reexamination, Control. No. 95/001,949. The Patent and Trademark Office granted reexamination and rejected all 29 claims as unpatentable. On appeal, the Patent Trial and Appeal Board (“the Board”) affirmed. Specifically, the Board’s final decision found claims 1-12, 14, 15, and 17-29 anticipated by U.S. Patent No. 6,496,867 to Beser (“Beser”), claims 1, 2, 7-9, 12-17, 19-21, and 24-29 anticipated by U.S. Patent No. 6,131,121 to Mattaway (“Matta-way”), and claims 1-15, 18-23, and 28-29 anticipated by U.S. Patent No. 6,557,037 to Provino (“Provino”). VirnetX now appeals to this court.

After full review of the record and careful consideration, we find no error in the Board’s claim constructions or findings with respect to the Mattaway and Provino references, which together cover all claims of the T81 patent. We do not, therefore, *790need to reach the merits of the Board’s decision with respect to Beser.

AFFIRMED
Exhibit 10.23
 (DEPARTMENT OF JUSTICE LOGO)
    
    U.S. Department of Justice
 
  
 
 Re: RAE Systems Inc.




---



##### 



- 2 -




---



##### 



With respect to this matter, from the date of execution of this Agreement forward,
this
Agreement supersedes all prior, if any, understandings, promises, and/or conditions between
the
Department and RAE Systems. No additional promises, agreements, or conditions have been
entered into
 - 3 -




---



##### 



- 4 -




---



##### 



APPENDIX A
 STATEMENT OF FACTS
  I.
    
    Background




---



##### 



II.
    
    RAE Systemss Government Customers in China
   - 2 -




---



##### 



III.
    
    RAE Systemss Knowing Failure to Implement Systems of
Effective Internal Controls at RAE-KLH and RAE Fushun Post Closing
     - 3 -




---



##### 



guanxi
 guanxi
 - 4 -




---



##### 



- 5 -




---



##### 



- 6 -




---



##### 



IV.
    
    Lack of Effective Internal Accounting Controls Permitted
Improper Payments to Continue at RAE-KLH and RAE Fushun After Acquisition
    - 7 -




---



##### 



A.
    
    RAE-KLH
    - 8 -




---



##### 



B.
    
    RAE Fushun
  V.
    
    Lack of Effective Internal Controls and Continued Improper Payments Led to Inaccurate Books and Records
   - 9 -




---



##### 



- 10 -




---



##### 



APPENDIX B
 CORPORATE COMPLIANCE PROGRAM
 et seq




---



##### 



- 2 -




---



##### 



- 3 -




---



##### 



- 4 -




---



##### 



- 5 -




---



##### 



- 6 -




---



##### 



APPENDIX C
 CORPORATE COMPLIANCE REPORTING




---



##### 



- 2 -
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM XIRCOM,
INC'S FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 1997 AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          SEP-30-1997
<PERIOD-START>                             OCT-01-1996
<PERIOD-END>                               JUN-30-1997
<CASH>                                          78,232
<SECURITIES>                                         0
<RECEIVABLES>                                   43,066
<ALLOWANCES>                                     3,424
<INVENTORY>                                     22,482       
<CURRENT-ASSETS>                               154,776
<PP&E>                                          35,874
<DEPRECIATION>                                  18,076
<TOTAL-ASSETS>                                 172,964
<CURRENT-LIABILITIES>                           41,797
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            23
<OTHER-SE>                                     126,746
<TOTAL-LIABILITY-AND-EQUITY>                   172,964
<SALES>                                        163,675
<TOTAL-REVENUES>                               163,675
<CGS>                                          104,208
<TOTAL-COSTS>                                  104,208
<OTHER-EXPENSES>                                46,510
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                 13,522
<INCOME-TAX>                                     4,056
<INCOME-CONTINUING>                              9,466
<DISCONTINUED>                                 (6,501)
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     2,965
<EPS-PRIMARY>                                      .14
<EPS-DILUTED>                                      .14
        

</TABLE>
# Third District Court of Appeal

State of Florida

Opinion filed November 1, 2017.

Not final until disposition of timely filed motion for rehearing.

________________

No. 3D16-1550

Lower Tribunal Nos. 14-261-A-K & 14-277-A-K

________________



### Glenn Steven Hanes

, Appellant,

vs.



### The State of Florida

, Appellee.

An Appeal from the Circuit Court for Monroe County, Wayne M. Miller

, Judge.

Carlos J. Martinez, Public Defender, and Harvey J. Sepler, Assistant Public

Defender, for appellant.

Pamela Jo Bondi, Attorney General, and Magaly Rodriguez

, Assistant

Attorney General, for appellee.

Before SUAREZ, LAGOA, and EMAS, JJ.

SUAREZ, J.

Glen Steven Hanes appeals from a final judgment of conviction and sentence

following a negotiated written plea agreement. Hanes argues that because the plea

colloquy was not thorough, the plea is involuntary.Generally, to obtain appellate review of a plea of guilty or no contest,

the defendant must specifically reserve dispositive issues for appeal or

file a motion to withdraw the plea in the trial court. Burns v. State

, 884 So. 2d 1010, 1012 (Fla. 4th DCA 2004). Following a guilty or no

contest plea, a defendant may appeal only the trial court's lack of

subject matter jurisdiction; a violation of a plea agreement, if

preserved by a motion to withdraw the plea; an involuntary plea, if

preserved by a motion to withdraw the plea; and a sentencing error, if

preserved. Fla. R. App. P. 9.140(b)(2)(A); Liebman v. State

, 853 So.

2d 514, 515 (Fla. 4th DCA 2003).

... An issue relating to the voluntary and intelligent nature of the plea

falls within the limited class of issues which a defendant may raise on

appeal from a guilty or no contest plea without having specifically

reserved the right to do so. Robinson v. State

, 373 So. 2d 898, 902

(Fla. 1979); Burns

, 884 So. 2d at 1013. However, before raising such

an issue on appeal, the defendant must first file a motion to withdraw

the plea with the trial court.

Garcia-Manriquez v. State

, 146 So. 3d 134 (Fla. 3d DCA 2014) (quoting Hicks v.

State

, 915 So. 2d 740, 741 (Fla. 5th DCA 2005)); see also Fla. R. App. P. 9.140.

Hanes concedes that he did not timely file a motion to withdraw the plea. As such,

we have no jurisdiction to entertain this appeal. We therefore dismiss without

prejudice for Hanes to pursue appropriate post-conviction remedies.

2
D.B.K. v. J.W.B.

2160502

Court of Civil Appeals of Alabama.

May 22, 2017

**DECISION WITHOUT PUBLISHED OPINION**

Dismissed.